Merck to create a separate cancer unit
Digest more
The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its ...
Merck said a treatment it is developing for HIV-1 met its primary endpoint in three Phase 3 trials. The biopharmaceutical company said Wednesday the results add to growing evidence for ...
Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), a Once-Daily, Two-Drug Regimen at CROI 2026 ...
Ahead of the looming loss of Keytruda’s exclusivity, the company is creating a standalone, cancer-focused unit and a second business housing its other drugs and vaccines.
Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this ...
Sales of Merck’s longtime oncology blockbuster Keytruda will erode more starkly in about 2033 rather than 2029, predicts ...
Merck has an attractive yield and a long history of dividend growth.
If you are wondering whether Merck's share price still offers value after a strong run, you are not alone. This article is ...
The new structure will help Merck as it slides toward a loss of exclusivity for Keytruda, pharma’s best-selling drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results